Elevated LH is common in polycystic ovary syndrome (PCOS), but is not part of the diagnostic criteria. LH concentrations are usually assessed in the early 'follicular' phase when it is suppressed, and therefore the prevalence is underestimated. In this study, LH is measured during the 'specific oligomenorrhoeic phase', when LH is least suppressed, and its importance as a diagnostic tool for PCOS is evaluated. Patients presenting with oligo-or amenorrhoea between 2002 and 2006 were selected, with the exclusion of women with WHO III oligoamenorrhoea, hyperprolactinaemia or with wrongly timed endocrine measurements. A total of 252 patients were included (198 oligo/amenorrhoeic PCOS patients and 54 oligo/amenorrhoeic controls).
INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility (Adams et al., 1986) and is characterized by symptoms of hyperandrogenism, oligo-or amenorrhoea, polycystic ovarian morphology, central obesity and insulin resistance. The presentation of PCOS symptoms is very heterogeneous, and this heterogeneity is the main reason for a continuous debate on the definition of PCOS (Azziz, 2005 (Azziz, , 2006 Franks, 2006) LH has been omitted from both diagnostic criteria as unnecessary (The Rotterdam ESHRE/ASRMSponsored PCOS Consensus Workshop Group, 2003) . LH has been assessed as a diagnostic test to discriminate between women with PCOS and healthy controls, and the LH/FSH ratio in particular was found to be predictive (Turhan et al., 1999) . Elevated LH is an inextricable feature of PCOS, found in about half of PCOS patients (Fauser et al., 1992; van Santbrink et al., 1997) , but the large variety in reported prevalence, from 35 to 77% (Deutsch et al., 1978; Robinson et al., 1992) , makes it difficult to use LH as a PCOS criterion. The cause of the high variability in prevalence of elevated LH is due to differences in the timing of LH sampling. Most studies measure LH in the early follicular phase (cycle day 3), but due to the intercycle variation of LH, the prevalence of high LH concentrations in PCOS is probably underestimated (van Hooff et al., 1999) . Temporary normalization of LH concentrations occurs in the luteal and early follicular phase and after progesterone-induced withdrawal bleeding (Minakami et al., 1988; Anttila et al., 1992) . The optimal time for measuring LH concentrations is when LH is minimally suppressed, and this is between at least 2 weeks from the start of the menstruation and at least 3 weeks before the next period. This phase is called the 'specific oligomenorrhoeic phase' (SOP) (van Hooff et al., 1999) , and only exists in cycles longer than 35 days.
The aim of the present study was to evaluate the prevalence of elevated LH concentrations in adequately timed samples in oligo/amenorrhoeic PCOS patients and oligo/amenorrhoeic controls, and to assess the importance of LH as a diagnostic tool for PCOS.
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MATERIALS AND METHODS

Patient and control population
Screening
According to local protocol, all patients with oligo-or amenorrhoea underwent transvaginal ovarian ultrasound, were evaluated for clinical signs of hyperandrogenism and underwent laboratory screening during the specific oligomenorrhoeic phase.
Pelvic ultrasound examination
Transvaginal pelvic ultrasound was performed in both PCOS patients and controls. PCOM was confirmed when 12 or more follicles (2-9 mm) in each ovary and/or increased ovarian volume 
Hyperandrogenism
Patients were diagnosed with hyperandrogenism in the presence of clinical and/or biochemical signs of androgen excess. For assessing hirsutism, nine body areas were screened and a Ferriman-Gallwey score of ≥8 was regarded as clinical hyperandrogenism (Ferriman and Gallwey, 1961) . Biochemical hyperandrogenism was diagnosed when testosterone was >2.5 nmol/l and/ or androstenedione >9.0 nmol/l. The normal ranges were obtained from the manufacturers, reUsing LH as a diagnostic criterion for PCOS 61 3 evaluated and confirmed in a local laboratory. Free testosterone concentrations could not be obtained, as sex hormone binding globulin was not measured.
Endocrine measurements
Laboratory screening was performed by the endocrine laboratory of the VU medical centre.
Plasma LH concentrations were determined by immunometric assay (Delfia, Wallac, Turku, Finland), with a lower detection limit of 0.3 IU/l and an intra-assay coefficient of variation of 4% at a concentration of 2 IU/l and of 3% at more than 3 IU/l. Androstenedione was measured using radioimmunoassay (DSL, Webster, Texas, USA) with a lower detection limit of 0.5 nmol/l.
Testosterone was analysed with a radioimmunoassay (Coat-A-Count; DPC, Los Angeles, USA) with a lower detection limit of 1.0 nmol/l. Oestradiol was determined by radioimmunoassay (DiaSorin, Saluggia, Italy) with a lower detection limit of 18 pmol/l. Progesterone was analysed using competitive immunoassay (Architect; Abbott Laboratories Diagnostic Division, Abbott Park, IL, USA) with a lower detection limit of 2 nmol/l.
Laboratory screening was performed during the specific oligomenorrhoeic phase. In practice, this meant that in patients with oligo/amenorrhoea, blood was sampled on cycle days 14 and 21, and once randomly in patients with amenorrhoea. Measurements that were retrospectively assessed as not performed within the specific oligomenorrhoeic phase were excluded (oestradiol ≥400 pmol/l and/or progesterone ≥5 nmol/l). When two or more adequately timed measurements were available, the measurement with the highest LH concentration was used in the analysis.
Of the included patients, women with low LH (≤2.0 IU/l), FSH (≤2.0 IU/l) and/or oestradiol (≤80 pmol/l) concentrations were diagnosed as hypogonadotrophic (WHO I).
Statistical methods
Statistical analysis was performed using SPSS software (version 12.0.1, Inc., Chicago, IL, USA).
A P-value of <0.01 was considered significant (Mainland, 1984) . In case of two independent groups, an independent Student's t-test was used to compare the normally distributed data, and for the comparison of three or more normally distributed groups variance analysis (ANOVA) was used in combination with the Bonferoni post-hoc test to identify differences between subgroups.
To test the diagnostic value of LH a receiver operating characteristics (ROC) curve was plotted, using the Rotterdam criteria as a gold standard. An optimal cut-off point was identified by calculating its associated sensitivity plus specificity at each LH concentration. The Pearson correlation coefficient was used to evaluate the correlation between variables.
RESULTS
Of the 392 oligo/amenorrhoeic patients 252 women were eligible for this study, consisting of 198 PCOS patients conforming to Rotterdam criteria and 54 oligo-/amenorrhoeic control patients 
LH as a diagnostic test for PCOS
The value of LH as a diagnostic test for PCOS was assessed with a ROC curve, using Rotterdam criteria as a gold standard. A curve close to the left upper corner was seen (Figure 3) , and several cut-off values of LH were analysed for its sensitivity and specificity (Table 2 ). An optimal cut-off point (highest specificity plus sensitivity) of LH was set at ≥6.5 IU/l. With this cut-off point, LH had a sensitivity of 84%, a specificity of 78%, positive and negative predicting values of 93 and 58% respectively and a likelihood ratio of 3.8. The area under the curve reached a value of 0.88 (0.83-0.93, 95% confidence interval). Assessment of the value of LH as a diagnostic test for the Rotterdam subgroups showed an optimal cut-off of ≥6.5 IU/l for patients with oligo/ amenorrhoea and hyperandrogenism (1990 NIH criteria), with a sensitivity and specificity of 85 and 78% respectively. The area under the curve was 0.89 (0.84-0.94, 95% confidence interval).
The subgroup with oligo/amenorrhoea and polycystic ovaries showed an optimal cut-off of ≥6.2 IU/l, resulting in a sensitivity of 90% and a specificity of 74%. The area under the curve reached a value of 0.89 (0.84-0.94, 95% confidence interval).
PCOS phenotypes
The Rotterdam criteria create four different PCOS phenotypes. Within the study population three phenotypic groups exist, women with all three criteria (OA, HA and PCOM) and two groups of patients with two out of the three criteria (OA + HA or OA + PCOM). Table 3 shows the mean hormone concentrations of these three groups of PCOS women and the controls. BMI was found to be higher in the PCOS group with all three diagnostic criteria compared with PCOS 
Oligomenorrhoea versus amenorrhoea
The 113 PCOS women with oligomenorrhoea and the 85 PCOS patients with amenorrhoea are compared in Table 4 . All features are comparable between these two groups. In the control group, LH was found to be significantly higher in the oligomenorrhoeic women than in amenorrhoeic patients (6.7 ± 3.4 and 3.0 ± 2.8 respectively, P < 0.001). The remaining hormonal values were comparable between the oligo-and amenorrhoeic control group (data not shown).
DISCUSSION
This study assessed the prevalence of elevated LH concentrations in adequately timed samples and its importance as a tool in the diagnosis of PCOS. High serum LH concentrations are often found in PCOS patients, and this is an inextricable feature of PCOS. An increased amplitude and frequency of pituitary LH pulses is seen in PCOS patients (Waldstreicher et al., 1988) , and it is postulated that LH hypersecretion is caused by insufficient gonadotropin surge attenuating factor (GnSAF) production resulting in increased pituitary priming (Balen and Jacobs, 1991; de Koning et al., 2001) . Besides causing ovulation and luteinization, LH is known to stimulate ovarian androgen production (Havelock et al., 2004) , and is seen as one of the main causes for hyperandrogenism in PCOS patients. The role of elevated LH concentrations in the pathogenesis of PCOS is unclear, and the question remains if it is part of the cause of PCOS or is a result of the endocrine and cycle disturbances. Testosterone (nmol/l) 1.7 ± 0.7 (n = 88) 1.8 ± 0.8 (n = 76)
Androstenedione (nmol/l) 8.1 ± 3.0 (n = 99) 8.9 ± 2.6 (n = 76) LH/FSH ratio 2.0 ± 0.9 (n = 111) 1.9 ± 1.0 (n = 84)
There were no significant differences between the two groups of patients.
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The more severe forms of PCOS seem to be associated with higher LH concentrations. Previous studies show that follicle number and ovarian volume are positively related to LH (Pache et al., 1993; Balen et al., 1995; Fulghesu et al., 2006) , and more severe cycle disturbances and an increased infertility rate were found with increasing LH concentrations in PCOS patients (Balen et al., 1995) . Furthermore, with increasing age and decreasing number of follicles, PCOS patients regain regular menstrual cycles (Elting et al., 2000) and concomitantly show lower LH concentrations (Bili et al., 2001) . A more pronounced decrease in LH concentrations is also seen in PCOS women responding to ovarian surgery to induce ovulation than in non-responders (Hendriks et al., 2007; Youssef and Atallah, 2007) . Thus, 'overcoming' PCOS and regaining regular menstrual cycles through ovarian surgery or by increasing age is accompanied by decreasing LH concentrations. Sufficient GnSAF production through adequate folliculogenesis could lower the pituitary sensitivity and subsequently cause lower LH production. In the PCOS woman, LH hypersecretion could be (partly) an expression of inadequate folliculogenesis, rather than a cause of the cycle disturbance. This is supported by the finding that regularly ovulating PCOS patients (with hyperandrogenism and polycystic ovarian morphology) show lower LH concentrations than patients with irregular cycles (Dewailly et al., 2006; Welt et al., 2006) . Furthermore, it was recently demonstrated that LH stimulates anti-Müllerian hormone (AMH) production in ovarian cells from PCOS patients (Pellatt et al., 2007) and subsequently can contribute to an arrest in folliculogenesis and development of the syndrome. It seems that high LH concentrations, besides being a common feature in PCOS, also reflect the severity of the syndrome.
In this study, elevated LH concentrations were found in a large majority of oligo-/amenorrhoeic PCOS patients, when measured during the specific oligomenorrhoeic phase. The reported prevalence in the literature of elevated LH concentrations in PCOS patients varies between 35 and 77% (Deutsch et al., 1978; Robinson et al., 1992) , but this study found a prevalence as high as 84%. This discrepancy can probably be fully explained by the intercycle variation of LH and the chosen timing of LH sampling. Most studies measure LH in the early 'follicular' phase, but due to suppression of LH concentrations during this phase by previous progesterone exposure, the prevalence of elevated LH concentrations is underestimated. LH is minimally suppressed during the specific oligomenorrhoeic phase, and a higher prevalence of elevated LH concentrations is found when LH is measured during this specific phase.
Furthermore, it is important to realize that investigators often compare PCOS patients to a 'healthy' control group, which might cause a bias (Bloom et al., 2006) . In daily practice, the clinical question usually is whether or not the oligo-/amenorrhoeic woman has PCOS, and due to the oligo/amenorrhoeic control group, this study is a close reflection of the daily clinical situation.
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To obtain at least one adequately timed LH sample, oligomenorrhoeic women should be screened at cycle days 14 and 21 and amenorrhoeic women once randomly. Assessment of progesterone can be added to ensure that ovulation has not occurred. This regimen has been used for years in the study centre, and is not difficult to use in practice. In spite of the variable length of the cycle in oligo/amenorrhoeic patients and the fact that the adequacy of timing can only be evaluated in retrospect, implementing this schedule for laboratory screening is successful in the majority of cases.
The diagnostic potency of LH was assessed in this study, and the results indicate that LH could be used as a diagnostic test to differentiate between PCOS and other causes of oligoor amenorrhoea. The ROC showed a curve close to the left upper corner and a satisfactory area under the curve of 0.88. Furthermore, a single elevation of LH concentrations in oligo-/ amenorrhoeic women predicted PCOS accurately in 93%, when using the optimal cut-off point in this assay of ≥6.5 IU/l, and a high sensitivity of 84% and a fair specificity of 78% were found. 
